Covestor’s Avadel Pharmaceuticals AVDL Stock Holding History

Covestor’s Portfolio AVDL Stock Details AVDL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-42,886	Closed	-$924K	–	2253
2025 Q4	$924K	Buy	42,886 +42,874	+357,283%	+$832K	0.48%	22
2025 Q3	$0	Sell	12 -146	-92%	-$1.9K	﹤0.01%	2278
2025 Q2	$1K	Buy	158 +101	+177%	+$887	﹤0.01%	1929
2025 Q1	$0	Buy	57 +36	+171%	+$301	﹤0.01%	2205
2024 Q4	$0	Buy	21 +14	+200%	+$170	﹤0.01%	2221
2024 Q3	$0	Buy	+7	New	+$107	﹤0.01%	2204

Other funds holding AVDL

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

HNB

Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Covestor's AVDL Position: Q1 2026 in Review

Covestor sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 42,886 shares — an estimated $924K sold.

Covestor first reported a position in AVDL in Q3 2024 and held it in 6 quarters. The position peaked at $924K in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.

Covestor reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Covestor sold 42,886 Avadel Pharmaceuticals shares in Q1 2026, an estimated $924K.
Covestor first reported a position in Avadel Pharmaceuticals in Q3 2024 and held it in 6 quarters.
Covestor's Avadel Pharmaceuticals position peaked at $924K in Q4 2025.
2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.